MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 3, 2005; DOI: 10.1124/mol.104.007062


0026-895X/05/6704-1237-1246$20.00
Mol Pharmacol 67:1237-1246, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.007062v1
67/4/1237    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Enguita, M.
Right arrow Articles by Trullas, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Enguita, M.
Right arrow Articles by Trullas, R.
Original Article

Glycogen Synthase Kinase 3 Activity Mediates Neuronal Pentraxin 1 Expression and Cell Death Induced by Potassium Deprivation in Cerebellar Granule Cells

Marta Enguita, Nuria DeGregorio-Rocasolano, Alba Abad, and Ramon Trullas

Neurobiology Unit, Institut d'Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

Abstract

Expression of neuronal pentraxin 1 (NP1) is part of the apoptotic cell death program activated in mature cerebellar granule neurons when potassium concentrations drop below depolarizing levels. NP1 is a glycoprotein homologous to the pentraxins of the acute phase immune response, and it is involved in both synaptogenesis and synaptic remodeling. However, how it participates in the process of apoptotic neuronal death remains unclear. We have studied whether the signaling pathways known to control neuronal cell death and survival influence NP1 expression. Both activation of the phosphatidylinositol 3-kinase/Akt (PI-3-K/AKT) pathway by insulin-like growth factor I and pharmacological blockage of the stress activated c-Jun NH2-terminal kinase (JNK) offer transitory neuroprotection from the cell death evoked by nondepolarizing concentrations of potassium. However, neither of these neuroprotective treatments prevents the overexpression of NP1 upon potassium depletion, indicating that nondepolarizing conditions activate additional cell death signaling pathways. Inhibiting the phosphorylation of the p38 mitogen-activated protein kinase without modifying JNK, neither diminishes cell death nor inhibits NP1 overexpression in nondepolarizing conditions. In contrast, impairing the activity of glycogen synthase kinase 3 (GSK3) completely blocks NP1 overexpression induced by potassium depletion and provides transient protection against cell death. Moreover, simultaneous pharmacological blockage of both JNK and GSK3 activities provides long-term protection against the cell death evoked by potassium depletion. These results show that both the JNK and GSK3 signaling pathways are the main routes by which potassium deprivation activates apoptotic cell death, and that NP1 overexpression is regulated by GSK3 activity independently of the PI-3-K/AKT or JNK pathway.


Received September 10, 2004; accepted January 3, 2005

Address correspondence to: Dr. Ramon Trullas, Neurobiology Unit, Institut d'Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Rosselló 161, 08036 Barcelona, Spain. E-mail: rtonbi{at}iibb.csic.es




This article has been cited by other articles:


Home page
NeurologyHome page
L. H. Wang, E. M. Johnson Jr, I. Shoulson, A. E. Lang, D. Bozyczko-Coyne, and On behalf of the Parkinson Study Group PRECEPT Inv
MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE
Neurology, August 5, 2008; 71(6): 462 - 463.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
D. Gozal, V. M. Crabtree, O. Sans Capdevila, L. A. Witcher, and L. Kheirandish-Gozal
C-reactive Protein, Obstructive Sleep Apnea, and Cognitive Dysfunction in School-aged Children
Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 188 - 193.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. A. Abad, M. Enguita, N. DeGregorio-Rocasolano, I. Ferrer, and R. Trullas
Neuronal Pentraxin 1 Contributes to the Neuronal Damage Evoked by Amyloid-{beta} and Is Overexpressed in Dystrophic Neurites in Alzheimer's Brain
J. Neurosci., December 6, 2006; 26(49): 12735 - 12747.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. D'Astous, P. Mendez, M. Morissette, L. M. Garcia-Segura, and T. Di Paolo
Implication of the Phosphatidylinositol-3 Kinase/Protein Kinase B Signaling Pathway in the Neuroprotective Effect of Estradiol in the Striatum of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mice
Mol. Pharmacol., April 1, 2006; 69(4): 1492 - 1498.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics